Prevention of nodules and enhancement of antibody response to genetically engineered recombinant vaccine against Human Chorionic Gonadotropin (hCG) for contraception

• Published in: The European journal of contraception & reproductive health care Vol. 29; no. 4; pp. 182 - 187
• Main Authors: Tiwari, Priyanka, Srivastava, Mala, Sehgal, Rohini, Kumar, Sunesh, Selvapandiyan, Angamuthu, Kumari, Anupma, Gupta, Jagdish C., Talwar, Gursaran Parshad
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis Ltd 01.08.2024
• Subjects: Adjuvants; Adjuvants, Immunologic; Animals; Antibody Formation - drug effects; Birth control; Chorionic Gonadotropin - immunology; Chorionic Gonadotropin, beta Subunit, Human - immunology; Contraception, Immunologic - methods; Female; Genetic Engineering; Humans; Injection Site Reaction; Injections, Intramuscular; Mice; Mice, Inbred BALB C; Vaccines; Vaccines, Contraceptive - immunology; Vaccines, Synthetic - immunology; recombinant vaccine; nodule; MIP; contraception; hCG
• ISSN: 1362-5187; 1473-0782; 1473-0782
• DOI: 10.1080/13625187.2024.2359127

Human Chorionic Gonadotropin (hCG) plays a crucial role in embryo implantation and in maintenance of pregnancy. An immuno-contraceptive approach involves the use of a recombinant hCGβ-LTB vaccine formulated with adjuvant Mycobacterium indicus pranii (MIP), to prevent pregnancy without disturbing ovulation, hormonal profiles, and menstrual cycles in women. The present work in mice was designed to address issues encountered in clinical trials conducted with hCGβ-LTB vaccine, with focus on two primary concerns. Firstly, it aimed to determine the optimal vaccine dosage required to induce a high level of anti-hCG antibodies. Secondly, it aimed to assess the safety profile of the vaccine, specifically injection site reactions in the form of nodules, observed in some of the subjects. Studies undertaken indicate that a 2 µg dose of the protein version of the vaccine, administered in mice through the intramuscular route, can induce high anti-hCG titres. Furthermore, administering a booster dose enhances the antibody response. Our findings suggest that the concentration and frequency of administration of the adjuvant MIP can also be reduced without compromising vaccine efficacy. The issue of nodule formation at the injection site can be mitigated either by administering the vaccine along with MIP intramuscularly or injecting hCG vaccine and MIP at separate intradermal sites. Thus, protein vaccine administered at a 2µg dose via the intramuscular route addresses both efficacy and safety concerns.